Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Articles|October 24, 2014
Gerresheimer Opens New Development Center in China
Gerresheimer AG announced that it has opened a new development center for medical plastic systems in Dongguan City, China. The new Technical Competence Center (TCC) in China will be managing large-scale projects.
Advertisement
Gerresheimer AG
“The new center in China ensures that we can optimally meet the growing demand in the Asian market,” said Andreas Schütte, member of Gerresheimer Management Board for Plastics & Devices, in a
The company currently has two other development centers in Wackersdorf, Germany and Peachtree City, US. Gerresheimer’s development centers produce medical plastic systems such as insulin pens, inhalers, lancets and auto-injectors for industrialization. All interdisciplinary functions up to a product’s series production stage are performed at these sites.
The local projects implemented at the development centers in collaboration with the other sites include series design, manufacturing equipment engineering, process development, project management, quality planning, tool making, automation technology, production initiation and pre-series production.
At its Dongguan City production facility, Gerresheimer has been manufacturing drug delivery devices such as inhalers and lancets for diabetes sufferers, and infusion products, since 2006.
Source:
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Advertisement
Advertisement